Leprosy Treatment Market Research Report- Global Forecast till 2023

Market Synopsis of Global Leprosy Treatment Market:

Market scenario:

Leprosy is a chronic infection caused by the bacteria *Mycobacterium leprae* or *Mycobacterium lepromatosis* causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The global market for leprosy is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.

Considering all these factors the market for leprosy treatment is expected to reach $ 3.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.

Study objectives:

- To provide a detailed analysis of the market structure along with estimated future growth forecast for the next six years about various segments and sub-segments of the global leprosy treatment market.
- To provide insights about factors affecting the market growth.
- To analyze the global leprosy treatment market based on various factors - Price Analysis, Supply Chain Analysis, Porters Five Force analysis etc.
- To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries - the Americas, Europe, Asia Pacific along with Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future growth prospects.
- To provide country level analysis of the market which includes segmentation by drug class, disease...
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market.

- To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments that are currently taking place in the global leprosy treatment markets.

**Research methodology**

**Sources:** World Health Organization (WHO), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centre for Health Informatics, India

**Key players of Global Leprosy treatment Market:**

Key players profiled in the report are Glaxo Smithline, Systopic Laboratories Pvt. Ltd., Cadila Pharmaceuticals, Acme Pharmaceuticals, Macleods Pharmaceuticals, Novartis International AG, Astra Zeneca, Lark Laboratories Ltd., and others.

**Segments:**

The global leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the market has been segmented as private, contract and others.
Regional analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.

The report for Global Leprosy treatment Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Intended Audience

- Global Leprosy treatment, manufacturers & suppliers
- Research and development (R&D) companies
- Market research and consulting service providers
- Academic institutes and universities
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:

2. RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:

3. MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS

4. MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY

5. GLOBAL LEPROSY TREATMENT MARKET, BY DRUG CLASS
5.1 SULFONE
5.2 PHENAZINE DERIVATIVE
5.3 ANTI-TUBERCULAR DRUGS
5.4 OTHERS

6. GLOBAL LEPROSY TREATMENT MARKET, BY DISEASE TYPE
6.1 PAUCIBACILLARY LEPROSY
6.2 MULTIBACILLARY LEPROSY

7. GLOBAL LEPROSY TREATMENT MARKET, BY MARKET CHANNEL
7.1 PRIVATE
7.2 CONTRACT
7.3 OTHERS

8. GLOBAL LEPROSY TREATMENT MARKET, BY REGION
8.1 NORTH AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
8.2.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10. COMPANY PROFILE

10.1 GLAXO SMITHCLINE

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 SYSTOPIC LABORATORIES PVT. LTD.

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 CADILA PHARMACEUTICALS

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 KEY DEVELOPMENT

10.4 ACME PHARMACEUTICALS

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 MACLEODS PHARMACEUTICALS

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 NOVARTIS INTERNATIONAL AG

10.6.1 OVERVIEW

10.6.2 PRODUCT OVERVIEW

10.6.3 FINANCIALS

10.6.4 KEY DEVELOPMENTS

10.7 ASTRA ZENECA

10.7.1 OVERVIEW

10.7.2 PRODUCT OVERVIEW

10.7.3 FINANCIALS

10.7.4 KEY DEVELOPMENTS
10.8 LARK LABORATORIES LTD.
10.8.1 OVERVIEW
10.8.2 PRODUCT OVERVIEW
10.8.3 FINANCIALS
10.8.4 KEY DEVELOPMENTS
10.9 OTHERS

11. CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF LEPROSY TREATMENT INDUSTRY

12. APPENDIX